Neuroimaging biomarkers for drug discovery and development in Schizophrenia

Schizophrenia is a chronic mental illness affecting up to 1% of the population. While therapies for positive symptoms are available and efficacious, cognitive and negative symptoms remain an unmet need after decades of research. New developments in the field of neuroimaging are accelerating our knowledge gain regarding the underlying pathophysiology of symptoms in schizophrenia and psychosis spectrum disorders, inspiring new targets for drug development. However, no validated and qualified biomarkers are currently available to support the development of new therapeutics.
Source: Biological Psychiatry - Category: Psychiatry Authors: Tags: Review Source Type: research